Literature DB >> 1973445

Antibody- and complement-mediated lysis of HIV-infected cells and inhibition of viral replication.

J P Gregersen1, S Mehdi, A Baur, J Hilfenhaus.   

Abstract

HIV-1-positive antisera were tested for their ability to lyse HIV-1-infected cells in the presence of active complement. Cytolytic effects caused by sera derived from infected humans were slower than those observed with sera from immunised chimpanzees. Lytic but also negative sera were found among HIV-1-infected asymptomatic men as well as among clinical AIDS cases. Human antisera that lysed infected cells reacted similarly irrespective of whether the complement was heterologous or autologous. Analysis of complement-mediated lysis using defined antisera against recombinant HIV-1 env or core antigens suggested that gp160/gp120 and p24 can act as target antigens for an antibody- and complement-mediated cytolysis of infected cells. Complement alone reduced the spread of HIV-1 infection in CD4+ cells and the ability of HIV-1 and HIV-2 to form plaques in CD4-transfected HeLa cells. Co-operative effects of specific antibodies and complement were the most effective in inhibiting HIV infections.

Entities:  

Mesh:

Year:  1990        PMID: 1973445     DOI: 10.1002/jmv.1890300411

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  9 in total

1.  A CD 4: immunoglobulin fusion protein with antiviral effects against HIV.

Authors:  J P Gregersen; S Mehdi; H Gelderblom; G Zettlmeissl
Journal:  Arch Virol       Date:  1990       Impact factor: 2.574

Review 2.  Complement and HIV-I infection/HIV-associated neurocognitive disorders.

Authors:  Fengming Liu; Shen Dai; Jennifer Gordon; Xuebin Qin
Journal:  J Neurovirol       Date:  2014-03-18       Impact factor: 2.643

3.  Analysis of Complement-Mediated Lysis of Simian Immunodeficiency Virus (SIV) and SIV-Infected Cells Reveals Sex Differences in Vaccine-Induced Immune Responses in Rhesus Macaques.

Authors:  Leia K Miller-Novak; Jishnu Das; Thomas A Musich; Thorsten Demberg; Joshua A Weiner; David J Venzon; Venkatramanan Mohanram; Diego A Vargas-Inchaustegui; Iskra Tuero; Margaret E Ackerman; Galit Alter; Marjorie Robert-Guroff
Journal:  J Virol       Date:  2018-09-12       Impact factor: 5.103

4.  Presence of parasite antigen on the surface of P388D1 cells infected with Ehrlichia risticii.

Authors:  J B Messick; Y Rikihisa
Journal:  Infect Immun       Date:  1992-08       Impact factor: 3.441

5.  Antibody-dependent complement-mediated cytotoxicity in sera from patients with HIV-1 infection is controlled by CD55 and CD59.

Authors:  J Schmitz; J P Zimmer; B Kluxen; S Aries; M Bögel; I Gigli; H Schmitz
Journal:  J Clin Invest       Date:  1995-09       Impact factor: 14.808

6.  Major histocompatibility complex-restricted CD8+ cytotoxic T lymphocytes from horses with equine infectious anemia virus recognize Env and Gag/PR proteins.

Authors:  T C McGuire; D B Tumas; K M Byrne; M T Hines; S R Leib; A L Brassfield; K I O'Rourke; L E Perryman
Journal:  J Virol       Date:  1994-03       Impact factor: 5.103

7.  Effect of complement on HIV-2 plasma antiviral activity is intratype specific and potent.

Authors:  Gülşen Özkaya Şahin; Birgitta Holmgren; Enas Sheik-Khalil; Zacarias da Silva; Jens Nielsen; Salma Nowroozalizadeh; Fredrik Månsson; Hans Norrgren; Peter Aaby; Eva Maria Fenyö; Marianne Jansson
Journal:  J Virol       Date:  2012-10-17       Impact factor: 5.103

8.  Efficacy of HIV-specific and 'antibody-independent' mechanisms for complement activation by HIV-infected cells.

Authors:  M N Saarloos; T F Lint; G T Spear
Journal:  Clin Exp Immunol       Date:  1995-02       Impact factor: 4.330

9.  Antiviral effects of different CD4-immunoglobulin constructs against HIV-1 and SIV: immunological characterization, pharmacokinetic data and in vivo experiments.

Authors:  K D Langner; M Niedrig; P Fultz; D Anderson; G Reiner; H Repke; H Gelderblom; B Seed; J Hilfenhaus; G Zettlmeissl
Journal:  Arch Virol       Date:  1993       Impact factor: 2.574

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.